TSE:4151Pharmaceuticals
Kyowa Kirin (TSE:4151) Valuation Check After New KOMZIFTI Menin Inhibitor Data in AML Trial
Kyowa Kirin (TSE:4151) just gave investors a fresh data point to chew on, with new KOMZIFTI combination trial results in acute myeloid leukemia highlighting encouraging activity alongside a clean looking safety profile.
See our latest analysis for Kyowa Kirin.
Those KOMZIFTI data land as Kyowa Kirin’s 90 day share price return of 7.9% and roughly 9% year to date share price gain suggest sentiment is quietly improving, even though the three year total shareholder return is still in negative...